Literature DB >> 29422212

Diagnosis and surveillance of late-onset fetal growth restriction.

Francesc Figueras1, Javier Caradeux2, Fatima Crispi2, Elisenda Eixarch2, Anna Peguero2, Eduard Gratacos2.   

Abstract

By consensus, late fetal growth restriction is that diagnosed >32 weeks. This condition is mildly associated with a higher risk of perinatal hypoxic events and suboptimal neurodevelopment. Histologically, it is characterized by the presence of uteroplacental vascular lesions (especially infarcts), although the incidence of such lesions is lower than in preterm fetal growth restriction. Screening procedures for fetal growth restriction need to identify small babies and then differentiate between those who are healthy and those who are pathologically small. First- or second-trimester screening strategies provide detection rates for late smallness for gestational age <50% for 10% of false positives. Compared to clinically indicated ultrasonography in the third trimester, universal screening triples the detection rate of late smallness for gestational age. As opposed to early third-trimester ultrasound, scanning late in pregnancy (around 37 weeks) increases the detection rate for birthweight <3rd centile. Contrary to early fetal growth restriction, umbilical artery Doppler velocimetry alone does not provide good differentiation between late smallness for gestational age and fetal growth restriction. A combination of biometric parameters (with severe smallness usually defined as estimated fetal weight or abdominal circumference <3rd centile) with Doppler criteria of placental insufficiency (either in the maternal [uterine Doppler] or fetal [cerebroplacental ratio] compartments) offers a classification tool that correlates with the risk for adverse perinatal outcome. There is no evidence that induction of late fetal growth restriction at term improves perinatal outcomes nor is it a cost-effective strategy, and it may increase neonatal admission when performed <38 weeks.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  fetal growth restriction; infant; late-onset disorders; newborn; small-for-gestational age; term birth

Mesh:

Year:  2018        PMID: 29422212     DOI: 10.1016/j.ajog.2017.12.003

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  30 in total

1.  Marijuana use, fetal growth, and uterine artery Dopplers.

Authors:  Ann M Bruno; Nathan R Blue; Amanda A Allshouse; David M Haas; Anthony L Shanks; William A Grobman; Hyagriv Simhan; Uma M Reddy; Robert M Silver; Torri D Metz
Journal:  J Matern Fetal Neonatal Med       Date:  2021-09-01

2.  The value of introducing cerebroplacental ratio (CPR) versus umbilical artery (UA) Doppler alone for the prediction of neonatal small for gestational age (SGA) and short-term adverse outcomes.

Authors:  Karla Leavitt; Linda Odibo; Chinedu Nwabuobi; Methodius G Tuuli; Anthony Odibo
Journal:  J Matern Fetal Neonatal Med       Date:  2019-07-21

3.  Interpretation of Wave Reflections in the Umbilical Arterial Segment of the Feto-Placental Circulation: Computational Modeling of the Feto-Placental Arterial Tree.

Authors:  Rojan Saghian; Lindsay Cahill; Anum Rahman; Joseph Steinman; Greg Stortz; John Kingdom; Christopher Macgowan; John Sled
Journal:  IEEE Trans Biomed Eng       Date:  2021-11-23       Impact factor: 4.538

4.  Developing a predictive model for perinatal morbidity among small for gestational age infants.

Authors:  Nathan R Blue; Amanda A Allshouse; William A Grobman; Robert C Day; David M Haas; Hyagriv N Simhan; Samuel Parry; George R Saade; Robert M Silver
Journal:  J Matern Fetal Neonatal Med       Date:  2021-09-28

Review 5.  MicroRNA-mRNA Networks in Pregnancy Complications: A Comprehensive Downstream Analysis of Potential Biomarkers.

Authors:  Asghar Ali; Frieder Hadlich; Muhammad W Abbas; Muhammad A Iqbal; Dawit Tesfaye; Gerrit J Bouma; Quinton A Winger; Siriluck Ponsuksili
Journal:  Int J Mol Sci       Date:  2021-02-25       Impact factor: 5.923

6.  Mechanisms of death in structurally normal stillbirths.

Authors:  Percy Pacora; Roberto Romero; Sunil Jaiman; Offer Erez; Gaurav Bhatti; Bogdan Panaitescu; Neta Benshalom-Tirosh; Eun Jung Jung; Chaur-Dong Hsu; Sonia S Hassan; Lami Yeo; Nicholas Kadar
Journal:  J Perinat Med       Date:  2019-02-25       Impact factor: 2.716

Review 7.  A literature review and best practice advice for second and third trimester risk stratification, monitoring, and management of pre-eclampsia: Compiled by the Pregnancy and Non-Communicable Diseases Committee of FIGO (the International Federation of Gynecology and Obstetrics).

Authors:  Liona C Poon; Laura A Magee; Stefan Verlohren; Andrew Shennan; Peter von Dadelszen; Eyal Sheiner; Eran Hadar; Gerard Visser; Fabricio Da Silva Costa; Anil Kapur; Fionnuala McAuliffe; Amala Nazareth; Muna Tahlak; Anne B Kihara; Hema Divakar; H David McIntyre; Vincenzo Berghella; Huixia Yang; Roberto Romero; Kypros H Nicolaides; Nir Melamed; Moshe Hod
Journal:  Int J Gynaecol Obstet       Date:  2021-07       Impact factor: 4.447

8.  Combined diffusion-relaxometry MRI to identify dysfunction in the human placenta.

Authors:  Paddy J Slator; Jana Hutter; Marco Palombo; Laurence H Jackson; Alison Ho; Eleftheria Panagiotaki; Lucy C Chappell; Mary A Rutherford; Joseph V Hajnal; Daniel C Alexander
Journal:  Magn Reson Med       Date:  2019-03-18       Impact factor: 4.668

9.  Paired maternal and fetal metabolomics reveal a differential fingerprint in preeclampsia versus fetal growth restriction.

Authors:  Lina Youssef; Rui V Simões; Jezid Miranda; María Luisa García-Martín; Cristina Paules; Francesca Crovetto; Nuria Amigó; Nicolau Cañellas; Eduard Gratacos; Fatima Crispi
Journal:  Sci Rep       Date:  2021-07-13       Impact factor: 4.379

10.  Metabolic profiling and targeted lipidomics reveals a disturbed lipid profile in mothers and fetuses with intrauterine growth restriction.

Authors:  Jezid Miranda; Rui V Simões; Cristina Paules; Daniel Cañueto; Miguel A Pardo-Cea; María L García-Martín; Francesca Crovetto; Rocio Fuertes-Martin; Monica Domenech; María D Gómez-Roig; Elisenda Eixarch; Ramon Estruch; Stefan R Hansson; Nuria Amigó; Nicolau Cañellas; Fatima Crispi; Eduard Gratacós
Journal:  Sci Rep       Date:  2018-09-11       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.